Advances in Serological Diagnosis of Chagas' Disease by Using Recombinant Proteins

Marcipar, Iván Sergio; Lagier, Claudia M.

doi:10.5772/28100

Cited by 2 publications

(3 citation statements)

References 121 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgM antibodies appear early in the acute phase of T. cruzi infection, and the SAPA has been shown to be a good marker for CD diagnosis by conventional serology. Moreover, anti-SAPA antibodies (IgM or IgG) have been detected in 90% of acute chagasic patients and in 7-10% of chronic patients [81]. This biosensor can distinguish between congenitally infected and non-infected infants when cord blood is tested, the sensitivity is in the ng/mL range (3.03 ng/mL) and the linear response between 10 and 200 ng/mL [80].…”

Section: Biosensorsmentioning

confidence: 96%

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

View full text Add to dashboard Cite

Chagas disease (CD), caused by Trypanosoma cruzi, affects millions of people worldwide. Although CD R&D has made progress during the last decade, clinicians and general practitioners are still facing the same challenge, i.e., the lack of adequate markers of clinical cure, hindering assessment of new drug efficacy in clinical trials and counseling of patients about treatment outcome. To date, no new markers have been validated as surrogates of seroreversion-the only marker of parasitological cure which is itself considered to be a surrogate of clinical benefit. T. cruzi DNA detected using PCR cannot currently be considered as a surrogate of seroconversion. Much emphasis has been placed on different T. cruzi antigens but no definite proof of correlation between titers, as determined by serology at a given timepoint, and seroreversion has been shown. Thanks to the improvement of analytical methods and the application of new methodologies, the identification of potential new markers is being facilitated, and some of these are progressing. However, there is a long journey from the identification of a potential biomarker to its clinical validation and acceptance by the regulatory authorities that requires a common effort from the entire Chagas community.

show abstract

Section: Biosensorsmentioning

confidence: 96%

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

View full text Add to dashboard Cite

show abstract

“…Several chimeric Ags have been described to be used for the diagnosis of CCD (da Silveira et al 2001; Marcipar and Lagier, 2012). These previously reported chimeras were composed mainly of different combinations of FRA, CRA, SAPA, TcD, MAP, B13, TcE, Tc29 T. cruzi Ags.…”

Section: Introductionmentioning

confidence: 99%

“…In order to improve the performance of an immunoassay prepared with multiple Ags, multiepitope proteins expressing several unrelated antigenic determinants have been also proposed (Houghton et al 1999(Houghton et al , 2000Aguirre et al 2006). This strategy would offer several advantages, such as (i) a decrease in the amount of Ags used in the immunoassays, (ii) controlled proportion of antigenic determinants that are displayed to Abs, (iii) increased number of epitopes available on the same surface, (iv) simpler production processes (da Silveira et al 2001;Marcipar and Lagier, 2012).…”

Section: Introductionmentioning

confidence: 99%

Development and assessment of an improved recombinant multiepitope antigen-based immunoassay to diagnose chronic Chagas disease

et al. 2018

View full text Add to dashboard Cite

The use of chimeric molecules fusing several antigenic determinants is a promising strategy for the development of low-cost, standardized and reliable kits to determine specific antibodies. In this study, we designed and assessed a novel recombinant chimera that complements the performance of our previously developed chimera, CP1 [FRA and SAPA antigens (Ags)], to diagnose chronic Chagas disease. The new chimeric protein, named CP3, is composed of MAP, TcD and TSSAII/V/VI antigenic determinants. We compared the performance of both chimeric Ags using a panel of 67 Trypanosoma cruzi-reactive sera and 67 non-reactive ones. The sensitivity of CP3 vs CP1 was 100 and 90.2%, and specificity was 92.5 and 100%, respectively. The mixture of CP1 + CP3 achieved 100% of sensitivity and specificity. More importantly, an additional subset of 17 sera from patients with discordant results of conventional serological methods was analysed; the CP1 + CP3 mixture allowed us to accurately classify 14 of them with respect to IIF, the usual technique used in most of the reference centres. These results show an improved performance of the CP1 + CP3 mixture in comparison with enzyme-linked immunosorbent assay and indirect haemagglutination commercial assays.

show abstract

Advances in Serological Diagnosis of Chagas' Disease by Using Recombinant Proteins

Cited by 2 publications

References 121 publications

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Development and assessment of an improved recombinant multiepitope antigen-based immunoassay to diagnose chronic Chagas disease

Contact Info

Product

Resources

About